Fosmidomycin, formerly known as FR-31564, is a protein synthesis inhibitor potentially for the treatment of plasmodium falciparum malaria. Fosmidomycin is an antibiotic that was originally extracted from culture broths of bacteria of the genus Streptomyces. It specifically inhibits DXP reductoisomerase, a key enzyme in the non-mevalonate pathway of isoprenoid biosynthesis. It is a structural analogue of 2-C-methyl-D-erythrose 4-phosphate. It inhibits the E. coli enzyme with a Ki of 38 nM, MTB at 80 nM, and the Francisella enzyme at 99 nM. References: Sooriyaarachchi S, Chofor R, Risseeuw MD, Bergfors T, Pouyez J, Dowd CS, Maes L, Wouters J, Jones TA, Van Calenbergh S, Mowbray SL. Targeting an Aromatic Hotspot in Plasmodium falciparum 1-Deoxy-d-xylulose-5-phosphate Reductoisomerase with β-Arylpropyl Analogues of Fosmidomycin. ChemMedChem. 2016 Sep 20;11(18):2024-36. doi: 10.1002/cmdc.201600249. Epub 2016 Aug 3. PubMed PMID: 27487410.

纯度：≥98%

CAS：66508-37-0